Wesper

Market position

Wesper positions itself in home sleep apnea testing as a clinically precise alternative to both in-lab PSG and to simpler home tests, claiming to be the first clinical-grade FDA-cleared wireless home sleep lab. It cites endorsements from sleep physicians including Dr. Atul Malhotra, Dr. Ruchir Patel and Dr. Kyle Schwab, and notes that only about 20% of people with obstructive sleep apnea are diagnosed, framing diagnosis access as the main market gap. It also links its opportunity to the growth of GLP-1 therapies for obesity-related OSA.

Wesper's stated differentiators are direct respiratory effort and cannula-equivalent airflow signals from a comfortable patch rather than a nasal cannula, a reported 95% AHI correlation to PSG (96% for the PPG-based Wesper Lite), no contraindications for arrhythmias or BMI, validation across diverse populations spanning ages, skin tones, BMIs and comorbidities, multi-night reusable testing that lowers per-test cost and enables retesting, and a two-tier ecosystem that lets clinics match test complexity to the patient on one platform, one record and one interpretation pipeline.

Technology

The system is built on flexible, wireless biometric sensor patches made of durable silicone with gentle adhesives for all-night wear. Wesper Lab captures thoracic and abdominal effort, body position, airflow, pressure, SpO2 and heart rate, sleep staging, snoring, movement, respiratory rate and skin temperature; Wesper Lite uses PPG. Data flows to a patient mobile app and a cloud-based provider portal, with AI/automated sleep apnea scoring algorithms (including an FDA-cleared sleep scoring algorithm integrated with Wesper Lab for total sleep time estimation), auto-scored reports with overscoring, EMR integration and chain-of-custody support. The founder's background is in flexible electronics.

Go-to-market

The company sells through healthcare providers, with "Book a Demo" as the primary conversion path and a separate provider portal and provider/patient instruction resources. Following its Series A it said it would build partnerships with sleep centers, dental clinics and coaches, expand its medical advisor network, and form strategic partnerships with hospitals, sleep labs and insurance providers. Content marketing through the Wesper Journal, published clinical validations, case studies and physician testimonials support the provider sales motion; named users include Circle Medical and a regional hospital system.

Healthcare providers and organizations that diagnose and manage sleep-disordered breathing: sleep clinics and sleep labs, hospital systems, primary care practices, dental clinics, bariatric/obesity medicine physicians, and surgeons managing hypoglossal nerve stimulation patients; patients are served through these providers.

Geography

A third-party listing places the company's headquarters in New York City, New York, USA, and the support line is a New York (917) area-code number. At the time of the Series A the company stated plans to bring the product to patients across the US. The CTO is described as based in Israel after 12 years in New York City.

History

Sources indicate the company was founded by Amir Reuveny, who was previously a postdoctoral fellow at Cornell Tech working on commercial applications of flexible electronics, together with CTO Adi Mordechai, previously a senior software engineer at Algotec and Director of Fraud Prevention at Matrix IF5. A third-party aggregator lists a 2017 founding and New York City headquarters. A seed round was reported in June 2020 and a Series A in November 2022; by the time of the Series A announcement the company described itself as FDA-cleared for home sleep apnea testing and as having onboarded key medical institutions. The current product line has expanded to two diagnostic tiers, Wesper Lab and Wesper Lite.

Risks & controversies

Sources disclose conflicting third-party funding data: an aggregator lists total funding of $11.8M across two rounds with a $7.5M Series A led by Ceros Capital Markets, while a press announcement describes a $9.6M Series A with Valor Equity Partners, Breyer Capital and Spark Capital participating; the same aggregator's employee range (1001-5000) appears inconsistent with the company's profile. Accuracy claims vary between 95% and 96% AHI correlation depending on product tier and source. No controversies or litigation are reported in the sources.